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Summary
Background Some countries fortify ﬂ our with folic acid to prevent neural tube defects but others do not, partly because 
of concerns about possible cancer risks. We aimed to assess any eﬀ ects on site-speciﬁ c cancer rates in the randomised 
trials of folic acid supplementation, at doses higher than those from fortiﬁ cation.
Methods In these meta-analyses, we sought all trials completed before 2011 that compared folic acid versus placebo, had 
scheduled treatment duration at least 1 year, included at least 500 participants, and recorded data on cancer incidence. 
We obtained individual participant datasets that included 49 621 participants in all 13 such trials (ten trials of folic acid 
for prevention of cardiovascular disease [n=46 969] and three trials in patients with colorectal adenoma [n=2652]). All 
these trials were evenly randomised. The main outcome was incident cancer (ignoring non-melanoma skin cancer) 
during the scheduled treatment period (among participants who were still free of cancer). We compared those allocated 
folic acid with those allocated placebo, and used log-rank analyses to calculate the cancer incidence rate ratio (RR).
Findings During a weighted average scheduled treatment duration of 5·2 years, allocation to folic acid quadrupled 
plasma concentrations of folic acid (57·3 nmol/L for the folic acid groups vs 13·5 nmol/L for the placebo groups), but 
had no signiﬁ cant eﬀ ect on overall cancer incidence (1904 cancers in the folic acid groups vs 1809 cancers in the 
placebo groups, RR 1·06, 95% CI 0·99–1·13, p=0·10). There was no trend towards greater eﬀ ect with longer treatment. 
There was no signiﬁ cant heterogeneity between the results of the 13 individual trials (p=0·23), or between the two 
overall results in the cadiovascular prevention trials and the adenoma trials (p=0·13). Moreover, there was no 
signiﬁ cant eﬀ ect of folic acid supplementation on the incidence of cancer of the large intestine, prostate, lung, breast, 
or any other speciﬁ c site.
Interpretation Folic acid supplementation does not substantially increase or decrease incidence of site-speciﬁ c cancer 
during the ﬁ rst 5 years of treatment. Fortiﬁ cation of ﬂ our and other cereal products involves doses of folic acid that are, 
on average, an order of magnitude smaller than the doses used in these trials.
Funding British Heart Foundation, Medical Research Council, Cancer Research UK, Food Standards Agency.
Introduction
Results from epidemiological studies of pregnant women 
showed that the intake of folate and the plasma 
concentration of folate early in pregnancy were both 
inversely associated with the incidence of neural tube 
defects, suggesting protection.1–3 Non-randomised4,5 and 
random ised6,7 intervention trials conﬁ rmed a protective 
eﬀ ect. Folate is now routinely recommended as a supple-
ment before and during pregnancy.8 Furthermore, 
population-wide folate fortiﬁ cation of ﬂ our for prevention 
of neural tube defects has been mandatory since 1998 in 
North America, resulting in a two-fold increase in popu-
lation plasma concentrations of folate.9,10 It is also 
mandatory in some other countries,9 including Chile, 
Argentina, Brazil, South Africa, and Australia;11–13 but not 
in New Zealand or in western European countries, partly 
because of concerns about possible adverse eﬀ ects on 
cancer incidence or prognosis.13–15
Results from epidemiological studies in other adult 
popu lations have also shown inverse (ie, apparently 
protective) associations of folate intake, and consequently 
of plasma concentrations of folate, with the incidence of 
cardiovascular disease16,17 and colorectal cancer.18 To test 
whether any real protective eﬀ ect exists against cardio-
vascular disease, placebo-controlled trials of about 5 years 
of folic acid supplementation were undertaken in some 
47 000 adults at high risk of vascular disease, and a 
collaborative meta-analysis of individual patient data on 
cancer incidence from all these trials was agreed pros-
pectively in 2004, before any results emerged.19,20 These 
trials did not suggest any protective eﬀ ect of folic acid 
supplementation against cardiovascular disease or 
against mortality from any cause during the scheduled 
trial treatment period.20
To test whether there is any real protective eﬀ ect 
against progression of colorectal adenomas, another 
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three such trials21–23 were undertaken in about 
3000 patients. One of these trials, the Aspirin and Folic 
Acid Polyp Prevention Study (AFPPS),21 reported in 
2007 unexpected increases in the incidence of advanced 
colorectal adenomas and of prostate cancer during 
7 years of treatment with folic acid. Also in 2007, it was 
suggested that transient increases in colorectal cancer 
incidence in Canada and the USA during 1996–98 might 
have been due to the 1996–98 introduction of folic acid 
fortiﬁ cation programmes in North America.24 Taken 
together, these reports (and awareness that anti-folate 
drugs such as methotrexate are used for the treatment 
of some cancers) prompted concerns about possible 
risks of cancer associated with folic acid supplements 
and folic acid fortiﬁ cation. Studies in animals had 
previously suggested the possibility that high intakes of 
folate could suppress the development of early lesions 
in normal tissue, but enhance the growth of estab-
lished neoplasms.25
To see whether, in aggregate, the randomised trials of 
folic acid show an increase or decrease in cancer risk 
over a period of just a few years, we present collaborative 
meta-analyses of site-speciﬁ c cancer incidence during 
the scheduled treatment period among 50 000 individuals 
from all available large cardiovascular and adenoma 
trials. We do not address the question of whether any 
eﬀ ects on cancer incidence will emerge some years or 
decades after the trials have ended.
Methods
Trial eligibility
We identiﬁ ed trials by searching PubMed using 
the search terms “randomized trials”, “folic acid”, 
“B-vitamins” or “homocysteine-lowering treatment”, and 
by scanning reference lists of trial reports (appendix p 3). 
Trials were eligible for inclusion if (1) at least one 
randomised comparison was folic acid versus placebo 
with scheduled treatment duration of at least 1 year 
(irrespective of whether any other treatment was tested 
factorially); (2) the trial included at least 500 participants; 
and (3) data on cancer incidence had been recorded. We 
sought for unpublished trials completed before 2011 
through electronic searches and discussions with other 
experts in the ﬁ eld, but did not ﬁ nd any. (As of Jan 1, 
2013, we still know of no such trials completed since 
2010.) We obtained individual participant datasets for all 
49 621 participants in the 13 trials21–23,26–35 completed by the 
end of 2010 (table 1, appendix p 6). Information about 
cancer incidence was not recorded in two other trials36,37 
with a total of 5992 participants. The protocol for trial 
identiﬁ cation, analysis and involvement of trialists was 
agreed following discussion with all collaborators before 
any cancer results emerged.19,20
Baseline and follow-up data
For each participant, we requested information about 
characteristics recorded before randomisation, allocated 
Number of 
patients 
randomised
Previous disease Main countries Mean (SD) 
scheduled 
duration of 
treatment 
(years)*
Daily dose 
of folic acid 
(mg)
Total 
number of 
incident 
cancers
Number of 
cancers (%) 
with known site 
of origin
Colorectal adenoma trials
UK CAP22 939 Adenoma UK 2·4 (1·3) 0·5 27 27 (100%)
Harvard23 692 Adenoma USA 5·3 (1·4) 1·0 49 48 (98%)
AFPPS21 1021 Adenoma USA 7·4 (1·7) 1·0 92 89 (97%) 
Subtotal 2652 ·· ·· 6·0 (1·6) ·· 168 164 (98%)
Vascular disease trials
VITRO26 701 CVD Netherlands 2·3 (0·7) 5·0 19 18 (95%)
HOST27 2056 Renal USA 2·9 (1·2) 40·0 137 135 (99%)
WENBIT28 3090 Coronary heart disease Norway 3·1 (1·0) 0·8 144 141 (98%)
NORVIT29 3749 Coronary heart disease Norway 3·0 (0·8) 0·8 149 135 (91%)
SU-FOL-OM330 2501 CVD France 4·4 (1·1) 0·6 171 170 (99%)
VISP31 3680 Stroke Canada and USA 1·8 (0·4) 2·5 187 88 (47%)
VITATOPS32 8164 CVD Australia, India, and UK 3·7 (2·3) 2·0 345 317 (92%)
WAFACS33 5442 CVD USA 6·9 (1·1) 2·5 414 384 (93%)
HOPE-234 5522 CVD or diabetes mellitus Canada and USA 4·6 (1·1) 2·5 662 650 (98%)
SEARCH35 12 064 Coronary heart disease UK 6·7 (1·5) 2·0 1317 1244 (94%)
Subtotal 46 969 ·· ·· 5·2 (1·3) ·· 3545 3282 (93%)
Total 49 621 ·· ·· 5·2 (1·3) 2·0† 3713 3446 (93%)
CVD=previous cardiovascular disease or increased risk of cardiovascular disease. *Mean (SD) in each trial, and weighted average of means (and of SDs) in subtotals and total 
(weighted by trial-speciﬁ c variance of logrank [O–E] for cancer). †Median value. 
Table 1: Design and eligibility criteria of included trials
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treatment, and the type and date (or time from ran-
domisation) of any cancer incidence or mortality during 
the scheduled treatment period. Information about 
admissions to hospital and cancer incidence was ob-
tained in each trial at 3–6 month intervals during the 
scheduled treatment period. Self-reported cancer was 
recorded, and additional infor mation on cancer incidence 
was, where possible,28–30,35 ob tained from national cancer 
registries. In one trial,31 the site of cancer onset was not 
recorded in the primary database, so we searched all 
relevant databases of adverse events in that trial to 
identify incident cancers. The other trials all sought 
veriﬁ cation of incident cancers from hospital electronic 
records or by writing to hospital or family physicians. 
Sites of cancer onset were available for 93% (3446/3713) 
of the cases.
We checked analyses of the individual participant 
data for consistency with any published reports and 
checked them with the trialists to ensure that the data 
were incorporated correctly into the meta-analysis. We 
asked investigators to conﬁ rm summary data for every 
treat ment group on the number of randomised 
participants, on plasma concentrations of folate and 
homocysteine before and after start of treatment, and 
on the number of participants who developed each of 
the predeﬁ ned outcomes.
The main outcome was incident cancer, deﬁ ned as the 
ﬁ rst occurrence after randomisation, but during the 
scheduled treatment period, of any cancer (ignoring non-
melanoma skin cancer). Where cancer was diagnosed 
only at death and no other information was available, we 
recorded the date of diagnosis as the date of death. Where 
cancer site was available only for mortality, we used this 
for analyses of incidence as well as mortality. We 
subdivided cancers into the 17 most common types, on 
the basis of the International Classiﬁ cation of Disease-10 
(ICD-10), with the aggregate of all other types as the 
18th category, and missing cancer code as the 
19th category. Having individual participant data from 
every trial facilitated uniform categorisation of cancer 
types (and permitted analyses of treatment eﬀ ects in 
prespeciﬁ ed subgroups).
Statistical analyses
We based comparisons of cancer rates by allocated 
treatment on intention-to-treat analyses of ﬁ rst events 
Figure 1: Eﬀ ects of folic acid allocation on overall ﬁ rst cancer incidence
RR=rate ratio. The black squares denote the RRs and horizontal lines the 99% CIs. Each square has an area inversely proportional to the variance of the log of the RR. 
The diamonds represent the summary estimates and their corresponding 95% CIs. *p=0·07. †p=0·20. ‡p=0·10.
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 63/1550 (4·1%)
 67/1877 (3·6%)
 78/1259 (6·2%)
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Treatment Control
1·20 (0·43–3·33)
0·94 (0·45–1·97)
1·63 (0·95–2·80)
1·33 (0·98–1·80)*
2·15 (0·62–7·44)
0·94 (0·61–1·47)
1·32 (0·86–2·04)
1·17 (0·76–1·78)
1·19 (0·80–1·76)
0·97 (0·67–1·42)
0·87 (0·66–1·15)
0·94 (0·73–1·21)
1·09 (0·89–1·33)
1·06 (0·92–1·23)
1·04 (0·98–1·11)†
1·06 (0·99–1·13)‡
99% CI
95% CI
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during the scheduled treatment period to calculate the 
event rate ratio (RR). The log-rank observed minus 
expected (o–e) statistics from each trial and their 
variances (v) were separately summed to produce, 
respectively, a grand total o–e statistic (G) and its variance 
(V).38 The one-step estimate of the log of the RR is then 
G/V with variance 1/V (and 95% CI G/V±1·96/√V). For n 
trials, a χ² statistic for heterogeneity with n–1 degrees of 
freedom (χ²n–1) is S–G²/V, where S is the sum over all 
trials of (o–e)²/v.
We assessed the eﬀ ects on cancer incidence in 
subgroups of year of follow-up (ﬁ rst 3 years or later), 
age, sex, plasma folate concentration, plasma homo-
cysteine concentration, and whether or not there was a 
nationwide folic acid fortiﬁ cation programme. We 
investigated heterogeneity of the RRs in these 
subgroups by a global χ² test to reduce the chance of 
misinterpreting any false positive results arising from 
multiple com parisons.39 We used 99% CIs for individual 
trials or subgroups (again to avoid misinterpreting false 
positive results), but used 95% CIs for the overall 
ﬁ ndings. To correct for multiple comparisons, p values 
for particular types of cancer were multiplied by the 
number of types investigated (to a maximum corrected 
p value of 1·0).40,41
To help reassess the hypotheses of increased incidence 
of colorectal adenoma and prostate cancer raised by 
AFPPS,21 we assessed the eﬀ ects of folic acid on colorectal 
and prostate cancer with and without exclusion of the 
AFPPS trial.40,41 The provision of (o–e) for each trial 
facilitates sensitivity analyses that exclude or include 
particular trials.
Folate reduces homocysteine, and the mean reduction 
in all trials was the weighted mean of study-speciﬁ c 
percent reductions in homocysteine, with weights pro-
portional to the variances of the log-rank statistics for 
overall cancer incidence. We used Statistical Analysis 
System (SAS) version 9.2.
Role of the funding source
The sponsors had no role in study design, data collection, 
data analysis, data interpretation, or writing or submission 
of the report. The Clinical Trial Service Unit and 
Epidemiological Studies Unit (CTSU) authors had full 
access to all the data and analyses and accept responsibility 
for this report. Final analyses and a draft report were 
circulated to all authors, revised and re-circulated. All 
authors are responsible for the decision to submit for 
publication.
Results
Individual participant datasets were obtained from all 
13 trials21–23,26–35 that met the inclusion criteria, including 
in total 49 621 participants (2652 from three trials21–23 in 
patients with a previous colorectal adenoma and 
46 969 from ten trials26–35 in people with, or at high risk of, 
cardiovascular disease; table 1). Two-thirds of the 
participants were men, and the mean age at entry was 64 
(SD 10) years (appendix p 6). The daily doses of folic acid 
ranged from 0·5 mg to 5 mg, except in one trial27 of a 
40 mg daily dose (table 1). All trials compared the eﬀ ects 
of folic acid versus placebo, except one trial31 that 
compared analyses of 2·5 mg versus 0·02 mg (5% of the 
recommended dietary intake; roughly equivalent to 
placebo). Mean scheduled treatment duration in diﬀ erent 
trials varied from 1·8 to 7·4 years, with weighted average 
5·2 years.
Allocation to folic acid was associated with quadrupling 
median plasma concentrations of folate (57·3 nmol/L for 
folic acid vs 13·5 nmol/L for placebo; except in the one 
trial of high-dose folic acid,27 where treatment produced 
more than a hundred-fold increase in plasma folate). It 
was also associated with a reduction by a quarter in 
plasma homocysteine con centrations (9·3 μmol/L for 
folic acid vs 12·3 μmol/L for placebo; except in the one 
trial where the pre-treatment homocysteine was already 
low,21 where treatment produced little further eﬀ ect on 
it; appendix p 7). As expected, eﬀ ects on plasma 
homocysteine concentrations appeared to be somewhat 
greater in populations not fortiﬁ ed with folic acid (27% 
reduction) than in fortiﬁ ed populations (20% reduction; 
appendix p 7).20
Information was available on 3713 patients with an 
incident cancer during the scheduled treatment period. 
Allocation to folic acid treatment did not have any 
signiﬁ cant eﬀ ect on overall cancer incidence, with 
1904 (7·7%) ﬁ rst events in 24 799 participants allocated 
folic acid versus 1809 (7·3%) in 24 822 allocated control 
(RR 1·06; 95% CI 0·99–1·13, p=0·10: ﬁ gure 1). No 
signiﬁ cant heterogeneity was noted between the results 
of all 13 trials or between the two subtotals for adenoma 
trials and vascular trials (ﬁ gure 1).
Importantly, we found no evidence of an increasing 
eﬀ ect of folic acid with increasing duration of treatment 
(ﬁ gure 2), although only four21,23,33,35 of the trials lasted 
more than 5 years. There were no signiﬁ cant diﬀ erences 
Figure 2: Eﬀ ects of folic acid on cancer incidence in all available trials, by year of follow-up
RR=rate ratio. The black squares denote the RRs and horizontal lines the 99% CIs. Each square has an area inversely 
proportional to the variance of the log of the RR. The diamonds represent the summary estimates and their 
corresponding 95% CIs.
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by sex, age, pretreatment blood concen tration of folate, 
pretreatment blood concentration of homocysteine, 
folic acid fortiﬁ cation in the population, folic acid dose, 
or percent homocysteine reduction (appendix pp 4–5). 
Even in the trial27 of 40 mg/day of folic acid, which 
produced more than a hundred-fold increase in plasma 
folate, no apparent increase was noted in overall cancer 
incidence (65 cancers in the folic acid group vs 72 cancers 
in the placebo group, RR=0·94; 99% CI 0·61–1·47; 
ﬁ gure 1).
We classiﬁ ed the 3713 cancers into 18 main types. 
There was no signiﬁ cant eﬀ ect of folic acid allocation 
compared with placebo on the incidence of colorectal 
cancer, lung, breast cancer, prostate cancer, any of the 
less common types, or cancer of an unknown type, either 
overall or by treatment duration (ﬁ gure 3, table 2).
Although there were conventionally signiﬁ cant pro-
tective eﬀ ects against oesophagus cancer during the ﬁ rst 
3 years but not later, and against breast cancer after 
3 years but not during the ﬁ rst 3 years (ﬁ gure 3), these 
unanticipated period-speciﬁ c protective eﬀ ects ceased to 
be signiﬁ cant when corrected for multiple comparisons 
(table 2). For adverse eﬀ ects, however, even before any 
such corrections, there were no conventionally sig niﬁ cant 
hazards for any type of cancer in either time period.
The appendix (pp 9–10) gives the log-rank statistics for 
colorectal and prostate cancer separately for each trial. We 
repeated the analyses after exclusion of the AFPPS trial,21 
which had reported a signiﬁ cant excess risk of colorectal 
adenomas and prostate cancer. Overall, the remaining 
trials did not support a signiﬁ cant adverse eﬀ ect on 
colorectal cancer (1·08; 95% CI 0·89–1·30; heterogeneity 
[AFPPS21 vs the other trials] χ²1=0·28, p=0·6) or prostate 
cancer (1·11; 95% CI 0·95–1·30; heterogeneity [AFPPS21 
vs the other trials] χ²1=4·46, p=0·03). The provision of 
(o–e) for each trial (appendix pp 9–11) facilitates additional 
sensitivity analyses that exclude particular trials.
Discussion
Both the hopes for rapid cancer prevention and the fears 
about rapidly increased cancer risk from folic acid 
supplementation were not conﬁ rmed by this meta-analysis 
of the trials of folic acid supplementation. Although the 
point estimate for overall cancer incidence was slightly 
increased, this ﬁ nding was compatible with a chance 
eﬀ ect, and the risk did not seem to increase with duration 
of treatment or daily dose of folic acid. Taking all studies 
together, allocation to folic acid for an average duration of 
5 years had no signiﬁ cant eﬀ ect on overall or site-speciﬁ c 
cancer incidence during the scheduled treatment period. 
Figure 3: Eﬀ ects of folic acid on ﬁ rst cancer incidence, by type and duration of treatment
RR=rate ratio. ICD=International Classiﬁ cation of Diseases. The black squares denote the RRs and horizontal lines the 99% CIs. Each square has area inversely proportional to the variance of the log of 
the RR. The diamonds represent the summary estimates and their corresponding 95% CIs.
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Par ticularly, supplementation had no signiﬁ cant eﬀ ect on 
the incidence of cancers of the large intestine (despite the 
epidemiological evidence of protection),18 prostate, lung, 
breast, or any other speciﬁ c site, either over all time periods 
or during the period more than 3 years after randomisation, 
although the power to detect diﬀ erences for cancer at 
particular sites at varying intervals of follow-up was 
limited. The results of the present meta-analysis, including 
49 621 participants, are unlikely to be biased by the 
unavailability of data on cancer incidence from two small 
trials, one of 1882 participants testing treatment with folic 
acid for 2 years36 and the other37 of 4110 participants testing 
treatment with folic acid for 4 years. Inclusion of the few 
cancer deaths recorded in those two trials would not 
materially alter the present meta-analyses of cancer 
incidence in all other trials.
A previous meta-analysis using summary data from a 
subset of the trials suggested a marginally signiﬁ cant 
excess of prostate cancer.42 The present meta-analysis, 
however, which used individual participant data in a time-
to-event analysis from all large trials, showed no signiﬁ cant 
excess of prostate cancer or of any other type of cancer. 
Thus, the apparent excess risk of prostate cancer from 
folic acid supplementation in the results of the AFPPS 
trial43 was most likely produced or exaggerated by the play 
of chance. Appropriate interpretation of such ﬁ ndings 
requires avoidance of unduly selective emphasis on 
particular trials, which can be achieved by analysing all 
trials, and by testing the hypothesis after excluding the 
results of the trial that generated the hypothesis.40,41 For, a 
striking excess of some type(s) of cancer in some 
individual trial(s) can be expected by chance alone when 
many diﬀ erent types of cancer are analysed separately in 
many diﬀ erent trials.
Although many of the trials used com binations of 
B vitamins (vitamin B12 and vitamin B6 in addition to 
folic acid), it is unlikely that this would have concealed 
any eﬀ ects of folic acid alone on cancer rates. The median 
daily dose of folic acid in the trials was 2·0 mg, which is 
greater than in most widely used vitamin supplements 
(0·1–0·8 mg) and an order of magnitude greater than the 
dose typically delivered by ﬂ our fortiﬁ cation programmes 
(0·1–0·4 mg).8
Despite the low doses provided by fortiﬁ cation, it had 
been suggested that transient increases in colorectal cancer 
incidence in Canada and the USA in 1996–98 (during the 
3-year period in which nationwide intro duction of folate 
fortiﬁ cation was being established) might have been due to 
folic acid.24 Although the increases in incidence of 
colorectal cancer recorded in the SEER cancer registries in 
<3 years after randomisation ≥3 years after randomisation All years
Folic 
acid
Control Uncorrected 
p value*
Corrected 
p value†
Folic 
acid
Control Uncorrected 
p value*
Corrected 
p value†
Folic 
acid
Control RR (CI)‡ Uncorrected 
p value*
Corrected 
p value†
Number of participants 
at start of time period
24 799 24 822 ·· ·· 17 292 17 363 ·· ·· 24 799 24 822 ·· ·· ··
Lip, mouth, pharynx 18 14 0·47 1·00 11 7 0·35 1·00 29 21 1·38 (0·66–2·86) 0·26 1·00
Oesophagus 7 21 0·01 0·14 16 11 0·34 1·00 23 32 0·72 (0·36–1·44) 0·22 1·00
Stomach 26 28 0·82 1·00 18 16 0·73 1·00 44 44 1·01 (0·58–1·75) 0·97 1·00
Liver or gall bladder 14 14 0·96 1·00 9 9 0·98 1·00 23 23 1·01 (0·47–2·15) 0·98 1·00
Pancreas 21 22 0·91 1·00 19 15 0·59 1·00 40 37 1·07 (0·59–1·93) 0·78 1·00
Colorectal 128 122 0·66 1·00 93 86 0·58 1·00 221 208 1·07 (0·83–1·37) 0·49 1·00
Larynx 5 7 0·56 1·00 3 2 0·64 1·00 8 9 0·89 (0·25–3·11) 0·81 1·00
Lung 154 138 0·35 1·00 118 115 0·78 1·00 272 253 1·08 (0·86–1·35) 0·37 1·00
Melanoma 33 26 0·35 1·00 31 36 0·55 1·00 64 62 1·04 (0·66–1·64) 0·84 1·00
Breast 79 65 0·25 1·00 61 92 0·01 0·17 140 157 0·89 (0·66–1·20) 0·30 1·00
Uterus 23 18 0·49 1·00 10 8 0·68 1·00 33 26 1·23 (0·63–2·41) 0·43 1·00
Ovary 7 9 0·60 1·00 9 9 0·99 1·00 16 18 0·88 (0·37–2·15) 0·72 1·00
Prostate 198 171 0·16 1·00 153 134 0·26 1·00 351 305 1·15 (0·94–1·41) 0·07 1·00
Kidney 30 30 1·00 1·00 26 20 0·37 1·00 56 50 1·12 (0·68–1·85) 0·56 1·00
Bladder 54 61 0·52 1·00 48 44 0·69 1·00 102 105 0·97 (0·68–1·39) 0·83 1·00
Brain 15 13 0·69 1·00 12 8 0·41 1·00 27 21 1·27 (0·60–2·69) 0·40 1·00
Haematological 66 62 0·74 1·00 51 54 0·80 1·00 117 116 1·01 (0·72–1·42) 0·94 1·00
Other sites 124 128 0·90 NA 85 56 0·02 NA 209 184 1·15 (0·88–1·49) 0·18 NA
Missing ICD/unspeciﬁ ed 93 97 0·78 NA 36 41 0·55 NA 129 138 0·94 (0·68–1·28) 0·58 NA
Total§ 1095 1046 0·26 NA 809 763 0·23 NA 1904 1809 1·06 (0·99–1·13) 0·10 NA
RR=rate ratio. ICD=International Classiﬁ cation of Diseases. NA=not applicable. *p values are two-sided, from log-rank analyses. †Corrected p values have been multiplied by the number of tests (17 sites) to allow 
for making multiple comparisons. ‡All are 99% CIs, except for “all cancers”, which is a 95% CI. §If non-melanoma skin cancer had been included, the number of people developing a cancer would have been 1989 
for the folic acid group versus 1890 for the control group. No deaths were attributed to this cause.
Table 2: Number of people with incident cancers at speciﬁ c sites, by duration of treatment
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the USA during 1996–98 are unexplained, they occurred 
too soon to be plausibly ascribable to the introduction of 
folate fortiﬁ cation during 1996–98, and did not persist after 
1998. Moreover, national trends in mortality from colorectal 
cancer in the USA at ages 35–69 years (which are unlikely 
to be inﬂ uenced by any artifactual trends in cancer 
detection or registration rates) showed no evidence of any 
new hazard after the introduction of fortiﬁ cation (ﬁ gure 4). 
Likewise, examination of US mortality rates at ages 
35–69 years from the other main types of cancer (data not 
shown) provides no good evidence of any hazard 
following fortiﬁ cation.
Our meta-analyses included all large trials of folic acid, 
but the power to exclude beneﬁ cial or adverse eﬀ ects on 
cancer at individual sites was limited by the number of 
cancers and the short duration of follow-up in these 
trials. Although the present meta-analyses address the 
eﬀ ects of folic acid supplementation on cancer during 
the scheduled trial treatment period, they do not address 
the question of whether any beneﬁ cial or harmful eﬀ ects 
on cancer incidence will eventually emerge among the 
participants many years after the trials all ended. Follow-
up for decades after the end of the trials might be feasible, 
especially in populations with automated record linkage 
to cancer registries and causes of death, but again, it will 
be important not to place unduly data-dependent 
emphasis on the results for speciﬁ c types of cancer in 
individual trials after particular follow-up durations.
Nevertheless, the human evidence about folic acid and 
cancer that has impeded folic acid fortiﬁ cation in the UK 
and some other countries involved possible increases in 
incidence of colorectal and prostate cancer within just 
the ﬁ rst few years of starting treatment, which, if real, 
should have been detectable during the trials. The 
present meta-analyses (which include the hypothesis-
generating trial) address this issue directly, showing that 
in aggregate, the trials provide no signiﬁ cant evidence of 
short-term eﬀ ects of folic acid supplementation on 
overall cancer incidence, or on the incidence of any 
particular type of cancer. The present meta-analysis rules 
out moderate increases in overall cancer incidence from 
folic acid supplementation during the trials. Large 
increases during the trials in any of the common types 
of cancer are similarly unlikely. Nationwide dietary 
fortiﬁ cation involves doses of folic acid that are an order 
of magnitude lower than the doses studied in these trials.
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